Windlas Biotech

Windlas Biotech P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Windlas Biotech (WINDLAS.NS) as of Nov 2, 2026 is 47.86. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 101.05 — a change of -52.64% (lower).

P/FCF

47.86

YoY

-52.64%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Windlas Biotech is 2026 47.86 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Windlas Biotech was 2025 101.05 . It decreases by -52.64% lower compared to the previous year.

The Windlas Biotech P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
166.60 INR
Jan 1, 2020
166.67 INR
Jan 1, 2021
288.21 INR
Jan 1, 2022
-284.81 INR
Jan 1, 2023
-162.82 INR
Jan 1, 2024
22.67 INR
Jan 1, 2025
101.05 INR
Jan 1, 2026
47.86 INR
The Windlas Biotech P/FCF history
YEARP/FCFYoY
47.86-52.64%
101.05+345.67%
22.67-113.92%
-162.82-42.83%
-284.81-198.82%
288.21+72.93%
166.67+0.04%
166.60-60.73%
424.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Windlas Biotech Stock analysis

What does Windlas Biotech do? Windlas Biotech Ltd. generates revenue through its CDMO services, offering product discovery, development, licensing, and commercial manufacturing for generic and complex generic pharmaceuticals across therapeutic areas like anti-diabetic, cardiovascular, neuropsychiatry, and respiratory therapies. The company provides formulation development, technology scale-up, and full-scale manufacturing for solid and liquid dosage forms, serving clients in the pharmaceutical industry. Additionally, Windlas markets its own nutraceutical, pharmaceutical, and ayurvedic products through a salesforce and distribution network spanning over 14 states, targeting semi-urban and rural communities. Its manufacturing facilities in Dehradun support both CDMO operations and in-house product production. The company's primary clients for CDMO services are pharmaceutical firms seeking development and manufacturing solutions for generic drugs. These clients benefit from Windlas's capabilities in formulation development, scale-up, and commercial production. The firm's own product line, sold via its distribution network, reaches semi-urban and rural consumers in India, complementing its CDMO business. Manufacturing in Dehradun enables efficient production for both external clients and internal product lines. Windlas Biotech's revenue streams include contract manufacturing for pharmaceutical companies and direct sales of its branded nutraceutical, pharmaceutical, and ayurvedic products. The CDMO segment focuses on complex generics in key therapeutic categories, while the in-house product line targets underserved communities with accessible healthcare solutions. The dual approach leverages the company's manufacturing infrastructure to serve both business-to-business and business-to-consumer markets. Windlas Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Windlas Biotech stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Windlas Biotech is 47.86 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Windlas Biotech changed from 101.05 to 47.86, representing a -52.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Windlas Biotech since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Windlas Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Windlas Biotech

All Key Metrics — Windlas Biotech